Aplex Bio

Aplex Bio

Aplex Bio develops next-generation hyperplexed PCR solutions. The technology is able to detect more than 100 target molecules in a sample – simultaneously and with ultra-high sensitivity down to one copy. Aplex Bio currently offers a broad panel of validated targets from different pathogens like SARS-COV-2 and others, and are constantly increasing its target base.

Aplex is based in Stockholm and is lead by Umear Naseem who founded the company. Aplex Bio joined NOME in 2021.